Efficacy and Safety of Bowel Cleansing with Mini S-Oral Sulfate Tablet versus the Conventional Oral Sulfate Tablet: A Prospective, Randomized, Investigator-Blinded, Multicenter, Noninferior, Phase 3 Trial
Gut and Liver · 2025
DOI: 10.5009/gnl250291 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Gut and Liver, 2025. Verfasst von Soo-Kyung Park und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Cathartics, Sulfates, Simethicone. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Taejoon Pharmaceuticals.
Abstract (Originalsprache)
Background/Aims: Conventional oral sulfate tablets (OSTs) and mini-OSTs have gained popularity for bowel preparation in South Korea. This study aimed to evaluate the efficacy, tolerability, and safety of mini S-OSTs, which have fewer tablets and include simethicone compared to the mini-OSTs.
Methods
This was a prospective, randomized, investigator-blinded, multicenter, and noninferior phase 3 trial conducted between August 2023 and January 2024. The efficacy, safety, and tolerability were compared among a mini S-OST split dose group, mini S-OST non-split dose group and conventional OST group. To evaluate the occurrence of gastric mucosal lesions, gastroscopy was also performed.
Results
High-quality preparation was achieved in the mini S-OST split dose group and conventional OST group according to both the full analysis set and per-protocol set analyses, without significant differences. Tolerability metrics were more favorable in the mini-OST group. The hematin content tended to decrease and the number of erosions was reduced in the mini S-OST split dose group compared with the conventional OST group according to the gastroscopy results. Adverse events were comparable between the conventional OST and mini S-OST split dose groups. The mini S-OST non-split dose group showed no difference in overall successful cleaning, but the proportion of high-quality cleaning in the ascending colon was lower than that in the mini S-OST split dose group and conventional OST group.
Conclusions
Compared with conventional OST, the mini S-OST split dose showed excellent efficacy, comparable safety and tolerability, with less gastric injury (ClinicalTrial.gov identifier NCT06287606).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Institute of Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine, Seoul, Korea.
- Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Gastroenterology, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul, Korea.
ORCID-Profile: Soo-Kyung Park, Seong Ran Jeon, Dong-Hoon Yang, Jaeyoung Chun, Jae Myung Cha
Förderung
- Taejoon Pharmaceuticals
Zitieren
APA
Park, S. K., Jeon, S. R., Yang, D. H., Chun, J., & Cha, J. M. (2025). Efficacy and Safety of Bowel Cleansing with Mini S-Oral Sulfate Tablet versus the Conventional Oral Sulfate Tablet: A Prospective, Randomized, Investigator-Blinded, Multicenter, Noninferior, Phase 3 Trial. Gut and Liver. https://doi.org/10.5009/gnl250291
Vancouver
Park SK, Jeon SR, Yang DH, Chun J, Cha JM. Efficacy and Safety of Bowel Cleansing with Mini S-Oral Sulfate Tablet versus the Conventional Oral Sulfate Tablet: A Prospective, Randomized, Investigator-Blinded, Multicenter, Noninferior, Phase 3 Trial. Gut and Liver. 2025. doi:10.5009/gnl250291
BibTeX
@article{Park2025,
author = {Park, Soo-Kyung and Jeon, Seong Ran and Yang, Dong-Hoon and Chun, Jaeyoung and Cha, Jae Myung},
title = {Efficacy and Safety of Bowel Cleansing with Mini S-Oral Sulfate Tablet versus the Conventional Oral Sulfate Tablet: A Prospective, Randomized, Investigator-Blinded, Multicenter, Noninferior, Phase 3 Trial},
journal = {Gut and Liver},
year = {2025},
doi = {10.5009/gnl250291}
}
EUVIMED